Celgene is testing Abraxane (nab-paclitaxel), which is approved to treat metastatic pancreatic cancer, as an adjuvant therapy in a late-stage trial,...
Read More...
The post Efficacy bar unclear for Celgene’s Phase III Abraxane/gemcitabine appeared first on Pharmaceutical Technology.
Original Article: Efficacy bar unclear for Celgene’s Phase III Abraxane/gemcitabine